

---

STATUTORY INSTRUMENTS

---

**2019 No. 775**

**The Human Medicines (Amendment  
etc.) (EU Exit) Regulations 2019**

**PART 3**

**Amendment of Part 3 (manufacture and distribution  
of medicinal products and active substances)**

**[<sup>F1</sup>Amendment of regulation 24 (standard provisions of licences)]**

**19A.** In regulation 24, after paragraph (2) insert—

“(3) In Schedule 4, in relation to a licence holder in Great Britain, references to the principles and guidelines set out in the Good Manufacturing Practice Directive are to those principles and guidelines as they apply under or by virtue of regulation B17.”.]

---

**Textual Amendments**

**F1** Reg. 19A inserted (31.12.2020 immediately before IP completion day) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, [Sch. 2 para. 13](#)

---

**Commencement Information**

**11** Reg. 19A in force at 31.12.2020 on IP completion day (in accordance with [2020 c. 1](#), [Sch. 5 para. 1\(1\)](#)), see [reg. 1](#)

**Changes to legislation:**

There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Section 19A.